Eslam Katab
@eslamkatab.bsky.social
Global Clinical Development Manager @ Sandoz
2021’s MIT innovators under 35
Pharmacist with PhD In Experimental Medicine @TU Munich
2021’s MIT innovators under 35
Pharmacist with PhD In Experimental Medicine @TU Munich
Reposted by Eslam Katab
📢 Shout out to @giampazolias.bsky.social - we made it to the 2️⃣0️⃣2️⃣4️⃣ year-end “Crick Five Stories”.
@crick.ac.uk
#CancerImmunology
#HostMicrobiome
🔗 Check out our original paper #OpenAccess:
www.science.org/doi/10.1126/...
@crick.ac.uk
#CancerImmunology
#HostMicrobiome
🔗 Check out our original paper #OpenAccess:
www.science.org/doi/10.1126/...
December 18, 2024 at 8:38 PM
📢 Shout out to @giampazolias.bsky.social - we made it to the 2️⃣0️⃣2️⃣4️⃣ year-end “Crick Five Stories”.
@crick.ac.uk
#CancerImmunology
#HostMicrobiome
🔗 Check out our original paper #OpenAccess:
www.science.org/doi/10.1126/...
@crick.ac.uk
#CancerImmunology
#HostMicrobiome
🔗 Check out our original paper #OpenAccess:
www.science.org/doi/10.1126/...
Reposted by Eslam Katab
🔭 What’s in store next for cell therapy for solid tumours?
2024 has been seismic with the @fda.gov approval of Lifileucel (melanoma) & Afami-cel (sarcoma).
Check out this outlook piece out today in Nat Cancer by Kishton & Restifo 👇
@natureportfolio.bsky.social
www.nature.com/articles/s43...
2024 has been seismic with the @fda.gov approval of Lifileucel (melanoma) & Afami-cel (sarcoma).
Check out this outlook piece out today in Nat Cancer by Kishton & Restifo 👇
@natureportfolio.bsky.social
www.nature.com/articles/s43...
T cells lead the charge against solid tumors - Nature Cancer
In 2024, two groundbreaking approvals from the US Food and Drug Administration for T cell-based therapies that target solid tumors were achieved. Lifileucel, a polyclonal tumor-infiltrating lymphocyte...
www.nature.com
December 17, 2024 at 9:50 PM
🔭 What’s in store next for cell therapy for solid tumours?
2024 has been seismic with the @fda.gov approval of Lifileucel (melanoma) & Afami-cel (sarcoma).
Check out this outlook piece out today in Nat Cancer by Kishton & Restifo 👇
@natureportfolio.bsky.social
www.nature.com/articles/s43...
2024 has been seismic with the @fda.gov approval of Lifileucel (melanoma) & Afami-cel (sarcoma).
Check out this outlook piece out today in Nat Cancer by Kishton & Restifo 👇
@natureportfolio.bsky.social
www.nature.com/articles/s43...
Reposted by Eslam Katab
Development of two next gen IO molecules has been discontinued. Vibostolimab (anti #TIGIT) and favezelimab (anti LAG3) programs both being shuttered. Development in this space has been significantly hampered by the lack of predictive biomarkers.
www.merck.com/news/merck-p...
www.merck.com/news/merck-p...
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab - Merck.com
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezeli...
www.merck.com
December 16, 2024 at 10:44 PM
Development of two next gen IO molecules has been discontinued. Vibostolimab (anti #TIGIT) and favezelimab (anti LAG3) programs both being shuttered. Development in this space has been significantly hampered by the lack of predictive biomarkers.
www.merck.com/news/merck-p...
www.merck.com/news/merck-p...
Longer PFS and lower high grade AEs in Nivolumab+AVD vs brentuximab vedotin + AVD in newly diagnosed stage III or IV Hodgkin lymphoma patients
www.nejm.org/doi/full/10....
#Immunotherapy #Nivolumab #Hodgkin_lymphoma
www.nejm.org/doi/full/10....
#Immunotherapy #Nivolumab #Hodgkin_lymphoma
Nivolumab+AVD improves progression-free survival in advanced-stage Hodgkin lymphoma | 2 Minute Medicine
1. This randomized controlled trial found that in patients with newly diagnosed stage III or IV Hodgkin lymphoma, treatment with nivolumab + AVD (N+AVD) led to longer progression-free survival compare...
www.2minutemedicine.com
December 1, 2024 at 9:09 PM
Longer PFS and lower high grade AEs in Nivolumab+AVD vs brentuximab vedotin + AVD in newly diagnosed stage III or IV Hodgkin lymphoma patients
www.nejm.org/doi/full/10....
#Immunotherapy #Nivolumab #Hodgkin_lymphoma
www.nejm.org/doi/full/10....
#Immunotherapy #Nivolumab #Hodgkin_lymphoma
Reposted by Eslam Katab
⭐️Development and phenotype of regulatory T cells
This picture is worth 100 K words!
Link to pdf: www.stemcell.com/media/files/...
This picture is worth 100 K words!
Link to pdf: www.stemcell.com/media/files/...
November 24, 2024 at 10:44 PM
⭐️Development and phenotype of regulatory T cells
This picture is worth 100 K words!
Link to pdf: www.stemcell.com/media/files/...
This picture is worth 100 K words!
Link to pdf: www.stemcell.com/media/files/...
A Phase I trial with GD2-targeted CAR T-cells shows promising results in agressive pediatric gliomas:
✅ Outcomes:
Tumor reduction: 52–100% in 4 patients.
Durable response: 30+ months in 1 patient.
Neurological gains in 9/11 patients.
✅ Safety: ICV delivery = fewer toxicities vs. IV.
#NeuroOncology
✅ Outcomes:
Tumor reduction: 52–100% in 4 patients.
Durable response: 30+ months in 1 patient.
Neurological gains in 9/11 patients.
✅ Safety: ICV delivery = fewer toxicities vs. IV.
#NeuroOncology
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas - Nature
We evaluated the use of chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) for H3K27M+ diffuse midline glioma (DMG), finding that intravenous administration of GD2-CART, followed by i...
www.nature.com
November 24, 2024 at 10:57 AM
A Phase I trial with GD2-targeted CAR T-cells shows promising results in agressive pediatric gliomas:
✅ Outcomes:
Tumor reduction: 52–100% in 4 patients.
Durable response: 30+ months in 1 patient.
Neurological gains in 9/11 patients.
✅ Safety: ICV delivery = fewer toxicities vs. IV.
#NeuroOncology
✅ Outcomes:
Tumor reduction: 52–100% in 4 patients.
Durable response: 30+ months in 1 patient.
Neurological gains in 9/11 patients.
✅ Safety: ICV delivery = fewer toxicities vs. IV.
#NeuroOncology
A shared meal, a kiss on the cheek: these social acts bring people together — and bring their microbiomes together, too. …. It is fascinating how our microbiome is shaped! www.nature.com/articles/d41...
Your friends shape your microbiome — and so do their friends
Analysis of nearly 2,000 people living in remote villages in Honduras reveals who’s spreading gut microorganisms to whom.
www.nature.com
November 23, 2024 at 12:53 PM
A shared meal, a kiss on the cheek: these social acts bring people together — and bring their microbiomes together, too. …. It is fascinating how our microbiome is shaped! www.nature.com/articles/d41...